Skip to content

    Cancer Clinical Trials

    A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer

    Learn more

    What is the purpose of this study?

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Eligibility

    • Has locally advanced or metastatic, histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of certain histologies
    • Has received 4 or more cycles of platinum-based doublet chemotherapy in first-line and a total of 6 to 8 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC)
    • Has platinum-sensitive epithelial OC
    • Has provided tissue of a tumor lesion that was not previously irradiated
    • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy
    • Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Part 1) or randomization (Part 2)
    • Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
    • Has an ECOG performance status of 0 or 1 assessed within 7 days before allocation (Part 1) or randomization (Part 2)

    Where can I participate?

    Hoag Hospital Irvine
    16200 Sand Canyon Ave
    Irvine, CA 92618


    Lauren Wagner

    lauren.wagner@hoag.org


    Hoag Hospital Newport Beach
    1 Hoag Dr
    Newport Beach, CA 92663


    Lauren Wagner

    lauren.wagner@hoag.org


    More about this Clinical Trial

    What is the full name of this Clinical Trial?

    A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

    • Disease Type/ConditionOvarian Cancer, Fallopian Tube Cancer
    • Principal InvestigatorTiffany L. Beck, MD
    • Co-InvestigatorsAlbert Mendivil, Lisa Abaid, John Brown, Monica Levine, Antonio Casteneda, Naz anvari, Andrea Beatty
    • Age GroupAdult, Older Adult
    • PhaseIII
    • ClinicalTrials.gov IDNCT06824467

    Hoag Family Cancer Institute

    Hoag Family Cancer Institute delivers advanced, compassionate cancer care across Orange County, with multidisciplinary specialists, precision therapies, support services, and access to 125+ cancer clinical trials. Patients benefit from research-driven care across a wide range of cancers, including breast, lung, gynecologic, prostate, gastrointestinal, and blood cancers.

    Learn More
    Dr. Grossman in a white coat writing on a board

    Stay up-to-date on the latest news from Hoag

    By submitting this request, you agree to receive communications from Hoag and accept our Privacy Policy and Terms of Use.